Valuation : TScan Therapeutics, Inc.

Market Cap 4.95Cr 4.26Cr 4Cr 3.65Cr 6.85Cr 470.61Cr 6.9Cr 47Cr 18Cr 238.73Cr 19Cr 18Cr 790.18Cr P/E 2026 *
-0.81x
P/E 2027 * -0.75x
Enterprise Value -4.94Cr -4.25Cr -3.99Cr -3.65Cr -6.85Cr -470.13Cr -6.9Cr -47Cr -18Cr -238.49Cr -19Cr -18Cr -789.39Cr EV / Sales 2026 *
-7.98x
EV / Sales 2027 * -3.89x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
19/08 TScan Therapeutics, Inc. And Amgen Inc. Terminate Research Collaboration And License Agreement CI
12/08 TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
30/07 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
22/06 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
22/06 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
03/06 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
06/05 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02/04 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
04/03 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
27/02 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
26/02 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
19/12 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
07/12 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
1 day-3.16%
1 week-8.71%
Current month-1.79%
1 month-1.79%
3 months-27.75%
6 months-29.50%
Current year-27.03%
1 week 0.72
Extreme 0.72085
0.81
1 month 0.72
Extreme 0.716
0.84
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
9.69
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Free

Director

67,000 0.1200%
20/05/26 Free

Director

67,000 0.1200%
20/05/26 Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
-3.16%-8.71%-58.30%-69.34% 5.11Cr
-1.66%-4.96%+49.84%+88.43% 6.95TCr
-2.19%+1.32%+44.54%+88.38% 6.5TCr
-3.57%-4.24%+47.11%+5.60% 2.65TCr
+2.77%-1.74%-16.16%+456.51% 2.59TCr
-0.46%-9.94%+0.98%-15.98% 2.56TCr
-9.71%-0.36%+245.87%+377.68% 2.02TCr
-1.58%+0.47%+29.35%-19.62% 2TCr
-3.36%-7.58%+9.47%+535.81% 1.57TCr
+0.35%+0.16%+46.96%+144.04% 1.35TCr
Average -2.26%-3.67%+39.97%+159.15% 2.82TCr
Weighted average by Cap. -2.02%-3.50%+48.06%+145.53%

Financials

2026 *2027 *
Net sales 61.88L 53.28L 50.03L 45.68L 85.74L 59Cr 86.37L 5.92Cr 2.3Cr 30Cr 2.32Cr 2.27Cr 99Cr 65.11L 56.06L 52.64L 48.07L 90.22L 62Cr 90.88L 6.23Cr 2.42Cr 31Cr 2.44Cr 2.39Cr 104.03Cr
Net income -12Cr -10Cr -9.6Cr -8.77Cr -16Cr -1.13TCr -17Cr -113.69Cr -44Cr -573.34Cr -45Cr -44Cr -1.9TCr -13Cr -11Cr -11Cr -9.64Cr -18Cr -1.24TCr -18Cr -125.04Cr -49Cr -630.55Cr -49Cr -48Cr -2.09TCr
Net Debt -9.89Cr -8.51Cr -7.99Cr -7.3Cr -14Cr -940.74Cr -14Cr -95Cr -37Cr -477.21Cr -37Cr -36Cr -1.58TCr -7.48Cr -6.44Cr -6.04Cr -5.52Cr -10Cr -711.32Cr -10Cr -72Cr -28Cr -360.83Cr -28Cr -27Cr -1.19TCr
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
138
Date Price Change Volume
31/26/31 $0.7297 -3.16% 3,29,748
28/26/28 $0.7535 +0.44% 1,50,791
27/26/27 $0.7502 -3.50% 2,88,103
26/26/26 $0.7774 -2.05% 68,396
25/26/25 $0.7937 -0.70% 1,80,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7535USD
Average target price
6.000USD
Spread / Average Target
+696.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock